Suven Life Sciences Ltd has obtained two product patents from Israel and one each from from Japan, China and New Zealand for its New Chemical Entities (NCEs).

In a release issued here on Friday, the Hyderabad-based company said the granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents.

``They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia,’’ it added.